JP2010539172A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539172A5 JP2010539172A5 JP2010524889A JP2010524889A JP2010539172A5 JP 2010539172 A5 JP2010539172 A5 JP 2010539172A5 JP 2010524889 A JP2010524889 A JP 2010524889A JP 2010524889 A JP2010524889 A JP 2010524889A JP 2010539172 A5 JP2010539172 A5 JP 2010539172A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- toxoid
- clostridium difficile
- sodium
- sucrose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 103
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 36
- 241000193163 Clostridioides difficile Species 0.000 claims description 30
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 22
- 229930006000 Sucrose Natural products 0.000 claims description 22
- 239000005720 sucrose Substances 0.000 claims description 22
- 239000003053 toxin Substances 0.000 claims description 21
- 231100000765 toxin Toxicity 0.000 claims description 21
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 20
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 17
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 12
- 239000001509 sodium citrate Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 10
- 235000011009 potassium phosphates Nutrition 0.000 claims description 10
- 239000001508 potassium citrate Substances 0.000 claims description 9
- 229960002635 potassium citrate Drugs 0.000 claims description 9
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 9
- 235000011082 potassium citrates Nutrition 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- 239000001488 sodium phosphate Substances 0.000 claims description 8
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 238000004220 aggregation Methods 0.000 claims description 6
- 230000002776 aggregation Effects 0.000 claims description 6
- -1 aluminum compound Chemical class 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 235000002639 sodium chloride Nutrition 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 102000015636 Oligopeptides Human genes 0.000 claims description 4
- 108010038807 Oligopeptides Proteins 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000008121 dextrose Substances 0.000 claims description 4
- 150000002170 ethers Chemical class 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 150000005846 sugar alcohols Polymers 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 230000001934 delay Effects 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 229960003964 deoxycholic acid Drugs 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000007951 isotonicity adjuster Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims description 2
- 239000011654 magnesium acetate Substances 0.000 claims description 2
- 235000011285 magnesium acetate Nutrition 0.000 claims description 2
- 229940069446 magnesium acetate Drugs 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 235000011147 magnesium chloride Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 239000012929 tonicity agent Substances 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims 11
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97249607P | 2007-09-14 | 2007-09-14 | |
| US60/972,496 | 2007-09-14 | ||
| PCT/US2008/010767 WO2009035707A1 (en) | 2007-09-14 | 2008-09-15 | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013241821A Division JP6258674B2 (ja) | 2007-09-14 | 2013-11-22 | クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539172A JP2010539172A (ja) | 2010-12-16 |
| JP2010539172A5 true JP2010539172A5 (enExample) | 2011-04-21 |
| JP5503543B2 JP5503543B2 (ja) | 2014-05-28 |
Family
ID=40452372
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010524889A Active JP5503543B2 (ja) | 2007-09-14 | 2008-09-15 | クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物 |
| JP2013241821A Active JP6258674B2 (ja) | 2007-09-14 | 2013-11-22 | クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物 |
| JP2016212540A Pending JP2017052773A (ja) | 2007-09-14 | 2016-10-31 | クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013241821A Active JP6258674B2 (ja) | 2007-09-14 | 2013-11-22 | クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物 |
| JP2016212540A Pending JP2017052773A (ja) | 2007-09-14 | 2016-10-31 | クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9320790B2 (enExample) |
| EP (3) | EP2198007B1 (enExample) |
| JP (3) | JP5503543B2 (enExample) |
| KR (2) | KR20160005378A (enExample) |
| CN (2) | CN106039299A (enExample) |
| AU (1) | AU2008299885C1 (enExample) |
| BR (1) | BRPI0816790A8 (enExample) |
| CA (1) | CA2699435A1 (enExample) |
| CY (1) | CY1119979T1 (enExample) |
| DK (1) | DK2198007T3 (enExample) |
| ES (2) | ES2657485T3 (enExample) |
| HR (1) | HRP20180054T1 (enExample) |
| HU (1) | HUE037932T2 (enExample) |
| IL (1) | IL204366A (enExample) |
| MX (1) | MX2010002815A (enExample) |
| NO (1) | NO2198007T3 (enExample) |
| PL (1) | PL2198007T3 (enExample) |
| PT (1) | PT2198007T (enExample) |
| RU (1) | RU2550271C2 (enExample) |
| SI (1) | SI2198007T1 (enExample) |
| WO (1) | WO2009035707A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009035707A1 (en) | 2007-09-14 | 2009-03-19 | Acambis Inc. | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
| EP3167899B1 (en) | 2010-09-03 | 2021-03-24 | Valneva Austria GmbH | Isolated polypeptide of the toxin a and toxin b proteins of c.difficile and uses thereof |
| GB201105981D0 (en) * | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
| MX391236B (es) | 2011-04-22 | 2025-03-21 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos. |
| KR101135486B1 (ko) * | 2011-05-25 | 2012-04-13 | 함종욱 | 보툴리눔 에이형 독소의 액상제품 |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| AU2013342163B2 (en) | 2012-11-08 | 2018-08-16 | F. Hoffmann-La Roche Ltd | IL-6 antagonists and uses thereof |
| AU2013354186A1 (en) | 2012-12-05 | 2014-06-12 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| CN111729077A (zh) | 2013-03-14 | 2020-10-02 | 武田疫苗股份有限公司 | 减毒活甲病毒制剂的组合物和方法 |
| US20160045586A1 (en) | 2013-03-15 | 2016-02-18 | Sanofi Pasteur, Inc. | Toxoid, Compositions and Related Methods |
| SG11201507578PA (en) * | 2013-03-15 | 2015-10-29 | Sanofi Pasteur Inc | Toxoid, compositions and related methods |
| SG11201510166YA (en) | 2013-06-14 | 2016-01-28 | Sanofi Pasteur Inc | Compositions and methods of immunizing against c. difficile |
| BR112015031541A2 (pt) | 2013-06-17 | 2017-07-25 | De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport | métodos para o impedimento da agregação de componentes virais |
| US9930893B2 (en) * | 2014-02-10 | 2018-04-03 | The Johns Hopkins University | Inhibitors of DXP synthase and methods of use thereof |
| DK4268843T3 (da) | 2014-11-07 | 2025-11-10 | F Hoffmann La Roche Ltd | Forbedrede IL-6-antistoffer |
| BR112017024443A2 (pt) | 2015-05-15 | 2018-10-23 | Sanofi Pasteur Inc | métodos para imunização contra clostridium difficile |
| BE1023343B1 (nl) * | 2015-05-20 | 2017-02-09 | Mycartis Nv | Opslagbuffer |
| US20190046642A1 (en) | 2016-02-23 | 2019-02-14 | Eleven Biotherapeutics, Inc. | Il-6 antagonist formulations and uses thereof |
| HUE046449T2 (hu) | 2016-09-13 | 2020-03-30 | Allergan Inc | Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények |
| KR102780168B1 (ko) * | 2018-05-21 | 2025-03-11 | 추가이 세이야쿠 가부시키가이샤 | 유리 용기에 봉입된 동결건조 제제 |
| US20230218735A1 (en) * | 2020-06-19 | 2023-07-13 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879218A (en) | 1982-09-13 | 1989-11-07 | Virginia Tech Intellectual Properties, Inc. | Antibody for C.difficile |
| US5736139A (en) * | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
| JPH03193735A (ja) | 1989-12-22 | 1991-08-23 | Shionogi & Co Ltd | グリコペプチド系抗生物質の安定化組成物 |
| DE69221252T2 (de) * | 1991-10-16 | 1998-01-22 | Schering Corp | Lipophile Zusammensetzungen von Oligosaccharid-Antibiotikasalzen |
| CA2138020C (en) | 1992-06-23 | 1999-02-16 | Eric A. Johnson | Pharmaceutical composition containing botulinum b complex |
| US5562909A (en) | 1993-07-12 | 1996-10-08 | Massachusetts Institute Of Technology | Phosphazene polyelectrolytes as immunoadjuvants |
| US5902565A (en) * | 1993-12-24 | 1999-05-11 | Csl Limited | Spray dried vaccine preparation comprising aluminium adsorbed immunogens |
| US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| JPH08333277A (ja) | 1995-06-05 | 1996-12-17 | Hoechst Japan Ltd | ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤 |
| CA2226392A1 (en) * | 1995-07-07 | 1997-01-30 | James S. Moncrief | Intranasal vaccination against gastrointestinal disease |
| US5932223A (en) | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| ATE346931T1 (de) * | 1997-06-20 | 2006-12-15 | Intervet Int Bv | Clostridium perfringens impfstoff |
| EP1568378B1 (en) | 1997-10-20 | 2016-03-16 | Sanofi Pasteur Biologics, LLC | Immunization against Clostridium difficile disease |
| DE69829400T2 (de) * | 1997-10-20 | 2006-04-13 | Acambis, Inc., Cambridge | Passive immunisierung gegen durch clostridium difficile verursachte krankheit |
| US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| US6013635A (en) * | 1998-05-28 | 2000-01-11 | Synsorb Biotech, Inc. | Treatment of C. difficile toxin B associated conditions |
| JP2000117967A (ja) * | 1998-10-16 | 2000-04-25 | Fuji Photo Film Co Ltd | インクジェット記録方法 |
| FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
| TR200103018T2 (tr) * | 1999-04-19 | 2002-02-21 | Beecham Biologicals S.A. Smithkline | İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri. |
| US6599715B1 (en) * | 1999-05-12 | 2003-07-29 | The Regents Of The University Of California | Real time viability detection of bacterial spores |
| US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| WO2003068259A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| AU2003225057A1 (en) * | 2002-04-19 | 2003-11-03 | The Regents Of The University Of Michigan | Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens |
| US20040235139A1 (en) * | 2002-12-23 | 2004-11-25 | Demain Arnold L. | Clostridium difficile culture and toxin production methods |
| DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| JP4671864B2 (ja) | 2003-10-09 | 2011-04-20 | 中外製薬株式会社 | タンパク質溶液の安定化方法 |
| BRPI0513850A (pt) * | 2004-07-26 | 2008-05-20 | Merz Pharma Gmbh & Co Kgaa | composição terapêutica com uma neurotoxina botulìnica |
| JP2008515996A (ja) | 2004-10-13 | 2008-05-15 | イリプサ， インコーポレイテッド | 毒素結合性オリゴ糖および重合体粒子を含有する医薬組成物 |
| FR2881139A1 (fr) * | 2005-01-26 | 2006-07-28 | Agronomique Inst Nat Rech | Composition pour la lyophilisation de proteines |
| BRPI0613001B8 (pt) | 2005-10-06 | 2021-05-25 | Allergan Inc | composições farmacêuticas de toxina clostrídica estabilizada por uma não-proteína |
| US8137677B2 (en) | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| WO2007044809A2 (en) * | 2005-10-11 | 2007-04-19 | Botulinum Toxin Research Associates, Inc. | Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use |
| CL2007003209A1 (es) | 2006-11-07 | 2008-05-09 | Acambis Inc | Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion |
| WO2009035707A1 (en) | 2007-09-14 | 2009-03-19 | Acambis Inc. | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
| JP2012510497A (ja) | 2008-12-03 | 2012-05-10 | ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ワクチンの生産方法 |
-
2008
- 2008-09-15 WO PCT/US2008/010767 patent/WO2009035707A1/en not_active Ceased
- 2008-09-15 PL PL08830210T patent/PL2198007T3/pl unknown
- 2008-09-15 CN CN201610227574.1A patent/CN106039299A/zh active Pending
- 2008-09-15 MX MX2010002815A patent/MX2010002815A/es unknown
- 2008-09-15 KR KR1020157036693A patent/KR20160005378A/ko not_active Abandoned
- 2008-09-15 SI SI200831906T patent/SI2198007T1/en unknown
- 2008-09-15 KR KR1020107007994A patent/KR101679812B1/ko not_active Expired - Fee Related
- 2008-09-15 PT PT88302104T patent/PT2198007T/pt unknown
- 2008-09-15 ES ES08830210.4T patent/ES2657485T3/es active Active
- 2008-09-15 CN CN200880116603.0A patent/CN101855336B/zh active Active
- 2008-09-15 HU HUE08830210A patent/HUE037932T2/hu unknown
- 2008-09-15 NO NO08830210A patent/NO2198007T3/no unknown
- 2008-09-15 BR BRPI0816790A patent/BRPI0816790A8/pt not_active IP Right Cessation
- 2008-09-15 AU AU2008299885A patent/AU2008299885C1/en not_active Ceased
- 2008-09-15 JP JP2010524889A patent/JP5503543B2/ja active Active
- 2008-09-15 DK DK08830210.4T patent/DK2198007T3/en active
- 2008-09-15 EP EP08830210.4A patent/EP2198007B1/en not_active Not-in-force
- 2008-09-15 HR HRP20180054TT patent/HRP20180054T1/hr unknown
- 2008-09-15 CA CA2699435A patent/CA2699435A1/en not_active Abandoned
- 2008-09-15 ES ES16174817T patent/ES3001561T3/es active Active
- 2008-09-15 RU RU2010114730/10A patent/RU2550271C2/ru not_active IP Right Cessation
- 2008-09-15 US US12/677,864 patent/US9320790B2/en active Active
- 2008-09-15 EP EP16174817.3A patent/EP3124044B8/en active Active
- 2008-09-15 EP EP24220340.4A patent/EP4537849A3/en active Pending
-
2010
- 2010-03-09 IL IL204366A patent/IL204366A/en active IP Right Grant
-
2013
- 2013-11-22 JP JP2013241821A patent/JP6258674B2/ja active Active
-
2016
- 2016-03-29 US US15/083,428 patent/US9687541B2/en active Active
- 2016-10-31 JP JP2016212540A patent/JP2017052773A/ja active Pending
-
2017
- 2017-06-26 US US15/632,480 patent/US10639362B2/en active Active
-
2018
- 2018-01-23 CY CY20181100084T patent/CY1119979T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539172A5 (enExample) | ||
| RU2010114730A (ru) | Фармацевтические композиции, содержащие анатоксины а и в clostridium difficile | |
| EP2709657B1 (en) | Thermostable vaccine compositions and methods of preparing same | |
| JP4902103B2 (ja) | 凍結乾燥フォームによる生物活性材料の保存 | |
| Ohtake et al. | Room temperature stabilization of oral, live attenuated Salmonella enterica serovar Typhi-vectored vaccines | |
| JP2014139229A5 (enExample) | ||
| CA2680193C (en) | Lyophilized preparation comprising influenza vaccine, and method for preparation thereof | |
| JP2011514337A5 (enExample) | ||
| JP2013515015A5 (enExample) | ||
| JP2012531442A5 (enExample) | ||
| KR20130064741A (ko) | 비강내 전달을 위한 방법 및 조성물 | |
| JP2015531377A5 (enExample) | ||
| CN104367558A (zh) | 一种奥司他韦冻干口崩片及其制备方法 | |
| CN106794145A (zh) | 热稳定冻干轮状病毒疫苗制剂及其制备方法 | |
| RU2014151424A (ru) | Термостабильные составы вакцины | |
| KR20180041237A (ko) | Vlp 안정화된 백신 조성물 | |
| BE1024685B1 (fr) | Compositions | |
| JP2018514564A5 (enExample) | ||
| US11224571B2 (en) | Oral dispersible vaccine comprising virosomes | |
| TW201625296A (zh) | 發泡性降低之疫苗組合物 | |
| US20230060631A1 (en) | Dry liposome adjuvant-containing vaccines and related methods thereof | |
| US9895321B2 (en) | Vaccines, methods of administering vaccines, methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration | |
| JPWO2023120535A5 (enExample) | ||
| US10973900B2 (en) | Dried composition | |
| US20140356396A1 (en) | Rotavirus preparations with excess calcium ions and high viscosities that ensure viability at elevated temperatures |